Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.
about
Targets for therapy in sarcomeric cardiomyopathiesGenetics of sudden cardiac death syndromesTp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathyHigh sensitivity of late gadolinium enhancement for predicting microscopic myocardial scarring in biopsied specimens in hypertrophic cardiomyopathyIdentifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal historyeIF4EBP3L acts as a gatekeeper of TORC1 in activity-dependent muscle growth by specifically regulating Mef2ca translational initiation.MEF2D deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death in vitro.Hypertrophic cardiomyopathy: translating cellular cross talk into therapeuticsInhibition of myocyte-specific enhancer factor 2A improved diabetic cardiac fibrosis partially by regulating endothelial-to-mesenchymal transition.Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments.Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy.Mechanisms of disease: hypertrophic cardiomyopathy.Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.Genetics of sudden cardiac death in the young.β-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes.Atrophied cardiomyocytes and their potential for rescue and recovery of ventricular function.Myocardial plasticity: cardiac development, regeneration and disease.Pro-survival function of MEF2 in cardiomyocytes is enhanced by β-blockersSmall dedifferentiated cardiomyocytes bordering on microdomains of fibrosis: evidence for reverse remodeling with assisted recovery.Ca(2+) leak in atrial fibrillation: junctophilin-2 stabilizes ryanodine receptor.Reversal of pathological cardiac hypertrophy via the MEF2-coregulator interface.Alteration of the ERK5 pathway by hydroxysafflor yellow A blocks expression of MEF2C in activated hepatic stellate cells in vitro: Potential treatment for hepatic fibrogenesis.New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy.Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy.A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity.Myocyte enhancer factor 2A promotes proliferation and its inhibition attenuates myogenic differentiation via myozenin 2 in bovine skeletal muscle myoblast.miR-133: A Suppressor of Cardiac Remodeling?
P2860
Q27027023-B27F07DE-DBE8-41D1-8111-24260BA4420BQ28307856-2761F3B6-5F6E-490F-88D9-3C0B91B3B7B5Q33168427-33B59C8E-DC84-41C5-9BB6-52908AF6C169Q33855587-49C07DF4-9DCE-4FEF-A083-D7E64D6F9CFEQ34772983-2B483FFF-70FF-43C1-B412-81D960872BB9Q35021553-F108E5D3-4A3A-4658-8815-EF823910D660Q36115841-FDBB0F07-2A47-43AF-9F9B-386D1789C14FQ36353490-0E78086A-2487-4F84-8279-01801D185D58Q37327651-6EDD449F-646D-4566-8076-65FC70840259Q37363558-883BFD7C-660B-44F7-B948-39317693AC63Q37384007-E3B7AB06-D8F4-49EE-AD11-417C7173335FQ37949516-4607FD3F-3C4D-4BDF-BC1B-E3830C86C431Q38125941-B6B6340C-0DFB-4BBA-AB26-7901A73899ABQ38259330-EC812708-D6A3-4C9D-A229-DED1ADC988EDQ38294845-55860FA4-C978-4530-A2EB-FEDE69F25ECCQ38731496-1398D8C4-8D11-4066-92A6-7FFEFDA8227FQ38920772-19C0C006-5120-4C99-AF6A-22823B830031Q39463779-4962A4B3-3615-4840-B528-50C990222D1DQ41906276-0B6673B2-5906-4D1F-8BD3-CA90D812E801Q42040664-0A23DE8F-1924-4F36-BE5D-F01B4882FC37Q42367637-8F18B463-41EC-4426-92F2-51CF48081DA6Q45953671-D282E019-1ECE-4F05-9A8A-8FACF2695C0EQ46572023-DCB90766-4ACF-42F8-8730-BE6A6EDA0363Q51446174-5B1F2FF2-2B75-4EF3-A306-35BD7B89C3A2Q51756006-EB1F9109-D4BF-4CE4-AB40-20B17CE3287BQ52561235-E81ACAD6-75B1-4510-BAF4-70A777313AFBQ58769694-63C77667-BACF-4D36-B4CA-7F2B6FBEC752
P2860
Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Heterogeneous myocyte enhancer ...... n hypertrophic cardiomyopathy.
@ast
Heterogeneous myocyte enhancer ...... n hypertrophic cardiomyopathy.
@en
Heterogeneous myocyte enhancer factor-2
@nl
type
label
Heterogeneous myocyte enhancer ...... n hypertrophic cardiomyopathy.
@ast
Heterogeneous myocyte enhancer ...... n hypertrophic cardiomyopathy.
@en
Heterogeneous myocyte enhancer factor-2
@nl
prefLabel
Heterogeneous myocyte enhancer ...... n hypertrophic cardiomyopathy.
@ast
Heterogeneous myocyte enhancer ...... n hypertrophic cardiomyopathy.
@en
Heterogeneous myocyte enhancer factor-2
@nl
P2093
P2860
P356
P1476
Heterogeneous myocyte enhancer ...... n hypertrophic cardiomyopathy.
@en
P2093
Christine E Seidman
Eric N Olson
Francisco J Naya
Hiroko Wakimoto
J G Seidman
Joshua M Gorham
Kumar Pandya
Libin Wang
Masataka Kawana
P2860
P304
18097-18102
P356
10.1073/PNAS.1012826107
P407
P577
2010-10-05T00:00:00Z